The first open-label study of psilocybin for treatment-resistant depression showed that changes in cerebral blood flow in the amygdala, measured with arterial spin-labelling MRI, correlated with changes in depression scores.

Authors

• Person: Not available Organization: Nature
  Neuroimaging in psychedelic drug development: past, present, and ...

Sources

• Neuroimaging in psychedelic drug development: past, present, and ... www.nature.com Nature via serper

Referenced by nodes (3)

• psilocybin concept
• treatment-resistant depression concept
• amygdala concept